Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation-specific and shows competitive binding effects.
We report here the in vitro use of hammerhead ribozymes as an approach to the gene therapy of osteogenesis imperfecta (OI). Our strategy for the treatment of this dominant genetic disorder is based on selective reduction of the level of the mRNA transcripts from the mutant allele. We studied the in vitro cleavage activity of five different hammerhead ribozymes targeted against synthetic transcripts of two naturally occurring human collagen mutations and against a point mutation introduced into a construct containing a portion of the mouse COL1A1 gene. This is the first demonstration that ribozyme cleavage is absolutely dependent on the presence of the ribozyme cleavage site introduced by the disease-causing mutation. Cleavage specificity and activity were unchanged when the cleavage site was located in transcripts of progressively longer length. Cleavage efficiency depended directly on the ratio of ribozyme/substrate, as well as on the time and temperature of incubation. We investigated the competitive effects of both total RNA and normal synthetic transcripts on ribozyme cleavage activity. The ribozyme was able to localize and cleave its specific target even in the presence of a vast excess of total RNA. However, cleavage efficiency was linearly inhibited by the presence of a non- cleavable competitor substrate which contained a ribozyme binding site identical to the site present in the cleavable target. Although this competition could be eliminated by introducing a mismatch into one ribozyme binding arm, the presence of the mismatch decreased ribozyme cleavage efficiency. The mutation- specificity of ribozyme cleavage demonstrated in this work provides support for in vivo studies aimed at ribozyme development as a treatment for dominant negative genetic disorders.
Grassi
G
G
Section on Connective Tissue Disorders, Heritable Disorders Branch, National Institutes of Child Health and Human Development, Building 10, Room 9s241, 10 Center Drive, MSC 1830, Bethesda MD 20892-1830, USA.
Forlino
A
A
Marini
J C
JC
D000818:Animals; D001483:Base Sequence; D001667:Binding, Competitive; D003094:Collagen / Q000235:genetics*; D004591:Electrophoresis, Polyacrylamide Gel; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010013:Osteogenesis Imperfecta / Q000235:genetics* / Q000628:therapy; D017354:Point Mutation; D012313:RNA / Q000378:metabolism*; D016337:RNA, Catalytic / Q000378:metabolism*
D016337:RNA, Catalytic; D012313:RNA; D003094:Collagen